# A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

> **NCT03345095** · PHASE3 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 749 (actual)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** Marizomib
- **DRUG:** Temozolomide
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT03345095
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-26
- **Primary completion:** 2022-08-23
- **Final completion:** 2023-06-30
- **Target enrollment:** 749 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345095, "A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03345095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*